{"transactions":[{"id":328,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-02T20:03:22.000Z","date":"2026-08-31","kind":"grant","planned":false,"acquired":true,"shares":21750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders."}],"balance_after":21750,"derivative":{"exercise_price":2.7,"expiration_date":"2036-08-31","underlying":"Common Stock","underlying_shares":21750},"source":{"system":"sec-edgar","filing":"0001187308-26-000004","document":"wk-form4_1788379399.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601485/000118730826000004/wk-form4_1788379399.xml","form_type":"4"}},{"id":747950,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T22:04:35.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares underlying the option vest on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":27.95,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001187308-26-000002","document":"form4-06052026_100631.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000118730826000002/form4-06052026_100631.xml","form_type":"4"}},{"id":1041600,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":22449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":22449,"derivative":{"exercise_price":15,"expiration_date":"2035-09-09","underlying":"Common Stock","underlying_shares":22449},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041599,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":10757,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":10757,"derivative":{"exercise_price":15,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":10757},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041598,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10757,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One fourth (1/4) of the shares subject to the option award vested on March 4, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":41.84,"expiration_date":"2034-03-03","underlying":"Common Stock","underlying_shares":10757},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041597,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":717,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":717,"derivative":{"exercise_price":15,"expiration_date":"2030-08-24","underlying":"Common Stock","underlying_shares":717},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041596,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":717,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.72,"expiration_date":"2030-08-24","underlying":"Common Stock","underlying_shares":717},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041595,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"grant","planned":false,"acquired":true,"shares":1792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":1792,"derivative":{"exercise_price":15,"expiration_date":"2028-06-26","underlying":"Common Stock","underlying_shares":1792},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1041594,"issuer":{"id":4678,"kind":"organization","name":"LB PHARMACEUTICALS INC","symbol":"LBRX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-12T22:25:18.000Z","date":"2025-09-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1792,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the \"Option Repricing\"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":69.72,"expiration_date":"2028-06-26","underlying":"Common Stock","underlying_shares":1792},"source":{"system":"sec-edgar","filing":"0001415889-25-024449","document":"form4-09122025_060913.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691082/000141588925024449/form4-09122025_060913.xml","form_type":"4"}},{"id":1140238,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-20T20:06:01.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":7900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after\nthe grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after\nthe grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":7900,"derivative":{"exercise_price":5.84,"expiration_date":"2035-05-19","underlying":"Common Stock","underlying_shares":7900},"source":{"system":"sec-edgar","filing":"0001601485-25-000085","document":"wk-form4_1747771551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000160148525000085/wk-form4_1747771551.xml","form_type":"4"}},{"id":1352503,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-25T12:34:21.000Z","date":"2024-11-21","kind":"grant","planned":false,"acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":4100,"derivative":{"exercise_price":5.12,"expiration_date":"2034-11-21","underlying":"Common Stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001601485-24-000093","document":"wk-form4_1732538054.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000160148524000093/wk-form4_1732538054.xml","form_type":"4"}},{"id":1697830,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-12-29T22:05:33.000Z","date":"2023-12-28","kind":"grant","planned":false,"acquired":true,"shares":4100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date."}],"balance_after":4100,"derivative":{"exercise_price":8.26,"expiration_date":"2033-12-28","underlying":"Common Stock","underlying_shares":4100},"source":{"system":"sec-edgar","filing":"0001140361-23-060233","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000114036123060233/form4.xml","form_type":"4"}},{"id":1809649,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T20:10:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3754,"price":7.51,"value":28192.54,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":7.41,"expiration_date":"2026-07-13","underlying":"Common Stock","underlying_shares":3754},"source":{"system":"sec-edgar","filing":"0001415889-23-012131","document":"form4-08112023_040811.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588923012131/form4-08112023_040811.xml","form_type":"4"}},{"id":1809648,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T20:10:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":4.9984,"value":3413.9072,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":9.9216,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":683},"source":{"system":"sec-edgar","filing":"0001415889-23-012131","document":"form4-08112023_040811.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588923012131/form4-08112023_040811.xml","form_type":"4"}},{"id":1809647,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T20:10:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":6.6439,"value":4537.7837,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one Contingent Value Right per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":8.2761,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":683},"source":{"system":"sec-edgar","filing":"0001415889-23-012131","document":"form4-08112023_040811.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588923012131/form4-08112023_040811.xml","form_type":"4"}},{"id":1882327,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-22T20:20:35.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024"}],"balance_after":8888,"derivative":{"exercise_price":0.6366,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-23-008498","document":"form4-05222023_040520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588923008498/form4-05222023_040520.xml","form_type":"4"}},{"id":2093168,"issuer":{"id":89417,"kind":"organization","name":"Aridis Pharmaceuticals, Inc.","symbol":"ARDS"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-12-07T14:01:43.000Z","date":"2022-12-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"5,000 shares of Common Stock will vest on June 5, 2023 and 5,000 will vest on 12/5/2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"5,000 shares of Common Stock will vest on June 5, 2023 and 5,000 will vest on 12/5/2023."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-22-034686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000149315222034686/ownership.xml","form_type":"4"}},{"id":2253003,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T21:00:47.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023."}],"balance_after":8888,"derivative":{"exercise_price":0.7632,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-22-005829","document":"form4-05272022_050530.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588922005829/form4-05272022_050530.xml","form_type":"4"}},{"id":2548425,"issuer":{"id":89417,"kind":"organization","name":"Aridis Pharmaceuticals, Inc.","symbol":"ARDS"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-10-05T22:51:44.000Z","date":"2021-10-04","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest in equal installments over 12 months, beginning on October 4, 2021."}],"balance_after":49791,"derivative":{"exercise_price":3.6,"expiration_date":"2031-10-04","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001104659-21-123286","document":"tm2129291-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000110465921123286/tm2129291-5_4seq1.xml","form_type":"4"}},{"id":2643988,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-02T20:16:05.000Z","date":"2021-07-01","kind":"exercise","acquired":false,"shares":6750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the underlying shares of common stock on July 14, 2017, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested."}],"balance_after":48805,"derivative":{"exercise_price":0.57,"expiration_date":"2026-07-13","underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0001415889-21-003398","document":"form4-07022021_040740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588921003398/form4-07022021_040740.xml","form_type":"4"}},{"id":2643987,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T20:16:05.000Z","date":"2021-07-01","kind":"sale","acquired":false,"shares":6750,"price":10.36,"value":69930.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.17 to $10.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-21-003398","document":"form4-07022021_040740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588921003398/form4-07022021_040740.xml","form_type":"4"}},{"id":2643986,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-02T20:16:05.000Z","date":"2021-07-01","kind":"exercise","acquired":true,"shares":6750,"price":0.57,"value":3847.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":6750,"source":{"system":"sec-edgar","filing":"0001415889-21-003398","document":"form4-07022021_040740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588921003398/form4-07022021_040740.xml","form_type":"4"}},{"id":2653190,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T11:15:26.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":8888,"price":9.97,"value":88613.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022."}],"balance_after":8888,"derivative":{"exercise_price":9.97,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-21-003240","document":"form4-06282021_070612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000141588921003240/form4-06282021_070612.xml","form_type":"4"}},{"id":2954963,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-07T22:49:06.000Z","date":"2020-12-03","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on the earlier of July 14, 2021 or the Company's next annual meeting of stockholders."}],"balance_after":8888,"derivative":{"exercise_price":18,"expiration_date":"2030-12-02","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001104659-20-132939","document":"tm2037869-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000110465920132939/tm2037869-4_4seq1.xml","form_type":"4"}},{"id":3438560,"issuer":{"id":89417,"kind":"organization","name":"Aridis Pharmaceuticals, Inc.","symbol":"ARDS"},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2019-08-14T23:27:06.000Z","date":"2019-08-13","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest in equal monthly installments over the 36 months following the date of grant."}],"balance_after":42791,"derivative":{"exercise_price":8.39,"expiration_date":"2029-08-13","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001104659-19-045979","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1187308/000110465919045979/a4.xml","form_type":"4"}},{"id":3891254,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-18T20:36:52.000Z","date":"2018-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments over a one-year period beginning on the grant date, provided that the final tranche will vest on the day immediately prior to the subsequent annual meeting."}],"balance_after":40000,"derivative":{"exercise_price":0.54,"expiration_date":"2028-06-14","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001437749-18-012012","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774918012012/rdgdoc.xml","form_type":"4"}},{"id":4108336,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-04T21:01:40.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the options vest in 12 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a one-year period beginning on January 31, 2018."}],"balance_after":25000,"derivative":{"exercise_price":1.18,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001437749-18-000259","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774918000259/rdgdoc.xml","form_type":"4"}},{"id":4257873,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":311,"kind":"person","name":"RUFFOLO ROBERT R","position":1,"cik":"0001187308","reported_name":"RUFFOLO ROBERT R","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2017-07-13T19:48:34.000Z","date":"2017-06-29","kind":"grant","acquired":true,"shares":52057,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the options vest in equal parts on the first three anniversaries of the grant date."}],"balance_after":52057,"derivative":{"exercise_price":2.31,"expiration_date":"2027-06-29","underlying":"Common Stock","underlying_shares":52057},"source":{"system":"sec-edgar","filing":"0001437749-17-012576","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774917012576/rdgdoc.xml","form_type":"4"}}]}